Aptose Biosciences, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of targeted oncology therapies. The company’s research primarily addresses hematologic malignancies and selected solid tumors with high unmet medical need. Leveraging its expertise in molecular biology and medicinal chemistry, Aptose seeks to advance precision medicines designed to inhibit critical oncogenic pathways and overcome treatment resistance.
The company’s lead product candidate, APTO-253, is a first-in-class small molecule that downregulates the oncogene c-Myc, which is overexpressed in a wide range of cancers. APTO-253 has completed Phase 1 clinical evaluation in patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), demonstrating a favorable safety profile and evidence of biological activity. In parallel, Aptose is developing CG-806, an oral, potent dual inhibitor of Bruton’s tyrosine kinase (BTK) and FMS-like tyrosine kinase 3 (FLT3), for the treatment of acute leukemias and B-cell malignancies. CG-806 is currently being evaluated in early-stage clinical trials, where it is designed to address resistance mechanisms associated with existing therapies.
Founded in the early 2000s and headquartered in Toronto, Canada, Aptose maintains research facilities and clinical operations in North America, enabling rapid advancement from laboratory bench to patient bedside. The company collaborates with leading academic institutions and leverages strategic partnerships to expand its development capabilities. Its multidisciplinary team of scientists, clinicians and industry veterans continues to explore novel drug targets and combination strategies, with the goal of delivering differentiated therapies to patients around the world.
Aptose is led by an experienced management team with deep expertise in oncology drug development, regulatory affairs and commercialization. The organization’s board and advisory committee include seasoned professionals from the biopharmaceutical sector, supporting robust governance and strategic guidance. By combining innovative science with a patient-centric approach, Aptose Biosciences aims to bring transformative treatments to those battling cancer.
AI Generated. May Contain Errors.
Free APTO Stock Alerts